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Summary
While particular combinations of mesodermal signals
are known to induce distinct tissue-specific programs
in the endoderm, there is little information about the
response pathways within endoderm cells that control
their specification. We have used signaling inhibitors
on embryo tissue explants and whole-embryo cultures
as well as genetic approaches to reveal part of an intra-
cellular network by which FGF signaling helps induce
hepatic genes and stabilize nascent hepatic cells
within the endodermal epithelium. Specifically, we
found that hepatic gene induction is elicited by an
FGF/MAPK pathway. Although the PI3K pathway is ac-
tivated in foregut endoderm cells, its inhibition does
not block hepatic gene induction in explants; however,
it does block tissue growth. We also found that at the
onset of hepatogenesis, the FGF/MAPK and PI3K
pathways do not crossregulate in the endoderm. The
finding of separate pathways for endoderm tissue
specification and growth provides insights for guiding
cellular regeneration and stem cell differentiation.
Introduction
The endoderm germ layer is patterned into liver, pan-
creas, lung, and other tissues by inductive signals
from mesoderm-derived cells (Wells and Melton, 1999;
Hogan and Zaret, 2002). Yet, the responsive signaling
pathways within endoderm cells that initiate genetic
programs for each tissue are unknown. Knowledge of
such pathways can provide insight into ontogeny, re-
generative responses, and the ability to prospectively
modulate stem cell differentiation. Embryo tissue re-
combination studies and genetic approaches have
shown that at least three different kinds of mesoderm
cells, including the cardiac mesoderm (Le Douarin,
*Correspondence: zaret@fccc.edu1975; Fukuda-Taira, 1981; Gualdi et al., 1996), the pro-
spective septum transversum mesenchyme (STM)
(Rossi et al., 2001), and endothelial cells (Matsumoto
et al., 2001), coordinately induce liver development in the
endoderm, apparently by employing different signaling
molecules (Zaret, 2002; Duncan, 2003). Here, we com-
bine diverse approaches to elucidate the response path-
ways within endoderm cells that elicit hepatic induction.
Fibroblast growth factor (FGF) signaling controls
many aspects of embryonic patterning, including liver
development. There are 18 mouse and human genes en-
coding FGF ligands and 4 genes encoding FGF receptor
(FGFR) tyrosine kinases (Itoh and Ornitz, 2004). Prior to
hepatic induction in the mouse ventral-lateral endoderm,
the adjacent cardiac mesoderm expresses Fgf8 and
Fgf10 (Crossley and Martin, 1995; Kelly et al., 2001; Cai
et al., 2003). At the time of hepatic induction, Fgf1 and
Fgf2 are also expressed in the cardiac mesoderm (Par-
low et al., 1991; Zhu et al., 1996; Jung et al., 1999), while
the ventral foregut endoderm expresses FGFR1 and
FGFR4 (Stark et al., 1991; Serls et al., 2005). Embryos ho-
mozygous for null alleles of Fgf8 or Fgfr1 die prior to liver
induction (Deng et al., 1994; Yamaguchi et al., 1994; Sun
et al., 1999). Embryos homozygous for null alleles of
Fgf1, Fgf2, Fgf10, or Fgfr4 survive to term and display
no defects in liver development (Weinstein et al., 1998;
Sekine et al., 1999; Miller et al., 2000), presumably due
to the functional redundancy of FGF signaling compo-
nents, which is common in the embryo (Bellusci et al.,
1997; Martin, 1998).
To circumvent such redundancy, we used soluble,
dominant-negative FGFR fusion proteins to block FGF
signaling extracellularly in explants of the cardiac meso-
derm and the ventral foregut endoderm (Jung et al.,
1999). Our findings demonstrated that FGF signaling
from the cardiac mesoderm is necessary for hepatic in-
duction (Jung et al., 1999; Deutsch et al., 2001; Serls
et al., 2005). Subsequently, FGF signaling was found to
be hepatogenic in Xenopus and chick endoderm ex-
plants (Chen et al., 2003; Zhang et al., 2004), fetal liver
progenitor cells (Spagnoli et al., 1998, 2000), and embry-
onic stem cells (Ishizaka et al., 2002; Schwartz et al.,
2002; Kubo et al., 2004). However, the role of FGF signal-
ing in hepatogenesis in intact embryos and the intracel-
lular pathways that induce hepatic genes have yet to be
elucidated.
FGF signaling generally activates the RAS/MAP kinase
(MAPK) and PI3 kinase/AKT pathways (Schlessinger,
2004; Bottcher and Niehrs, 2005), which can be selec-
tively blocked by inhibitors. Sprouty (Spry) genes were
first discovered as negative feedback inhibitors of FGF
signaling in Drosophila (Hacohen et al., 1998), but they
were later found to inhibit signaling mediated by tyrosine
kinase receptors (RTKs) for FGF, EGF, and GDNF (Casci
et al., 1999; Kramer et al., 1999; Reich et al., 1999; Bas-
son et al., 2005; Shim et al., 2005). The specific intracel-
lular pathways affected by different Sprouty genes are
under investigation (Kim and Bar-Sagi, 2004).
In this study, we used two transgenic mouse lines
that target Cre recombinase expression to foregut
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Spry2 gain-of-function transgene. We also employed
small-molecule inhibitors to block potential FGF sig-
naling pathways in cultured mouse embryos and
endoderm-mesoderm explants, and we biochemically
analyzed the effect on phosphorylated pathway inter-
mediates. The studies reveal a separation of path-
ways that initiate hepatic gene expression and initial
growth and thus unveil part of the network within endo-
derm cells by which extracellular signals initiate hepato-
genesis.
Results
Active MAPK and PI3K Signaling in Prospective
and Nascent Hepatic Endoderm Cells
Since the MAPKs ERK1 and ERK2 have been implicated
in embryonic FGF signaling (Corson et al., 2003), we ex-
amined the locations of cells containing phosphorylated
ERK1/2 (P-ERK) by whole-mount immunohistochemis-
try on E8.25–8.5 mouse embryos, both prior to (2–5 so-
mite pairs; 2–5S) and at the time of (7–8S) hepatic spec-
ification (Gualdi et al., 1996; Jung et al., 1999; Serls et al.,
2005). Fate mapping studies of the ventral foregut endo-
derm have shown that the embryonic liver is derived
from lateral endoderm cells, caudal to the foregut open-
ing, and a small cluster of ventral midline endoderm cells
(Tremblay and Zaret, 2005). The prospective liver do-
mains are separated, at the 2–5S stages, by progenitors
of anterior foregut tissues. At these stages, we detected
P-ERK in the lateral liver progenitors (Figures 1A and 1B,
green arrows; Figure 6 below), but not in the medial liver
progenitors (Figures 1A and 1B, black arrows). However,
by the 7–8S stage, when hepatic induction occurs, the
medial liver progenitors also exhibited active MAPK
signaling (Figure 1C, middle green arrow; sections not
shown). Section analysis showed that the positive cells
were localized in the gut endoderm and the adjacent
cardiac mesoderm (Figures 1A0–1C0). Only a few other
embryonic domains, including the head fold ectoderm
(Figure 1C, h.f.) and allantoic bud (not shown), appeared
to be P-ERK-positive at these stages. A 30 min incuba-
tion of 7–8S embryos in medium containing 40 mM
SU5402, an inhibitor of FGFR tyrosine kinase signaling
(Mohammadi et al., 1997), depleted the P-ERK signal
(Figures 1D and 1D0, black arrows). Control embryos cul-
tured in the DMSO vehicle retained P-ERK (data not
shown). We conclude that MAPK signaling is active in
lateral prospective liver cells prior to hepatic induction,
and in both medial and lateral prospective liver cells at
the time of hepatic induction.
Further analysis showed that, prior to hepatic induc-
tion (4S), the foregut endoderm is negative for P-AKT
(Figure 1E, black arrows), whereas at the time hepatic
genes are activated (7–8S), most of the ventral foregut
endoderm is P-AKT positive, including medial and
lateral hepatic progenitors (Figure 1F, green arrows).
Section analysis showed that P-AKT is restricted to
endodermal cells and was not detected in the cardiac
mesoderm (Figure 1F0, green arrow). Together, these
data show that both the MAPK and PI3K pathways
are activated in nascent hepatic endoderm cells, but
that the MAPK pathway is activated prior to hepatic
induction.Separate Pathways Controlling the Initiation
of Hepatic Gene Expression and Growth
in Endoderm Explants
Next, we generated explant cultures of the ventral fore-
gut endoderm, the cardiac mesoderm, and STM cells
from E8.25 embryos (2–4S), when the liver gene program
is not yet activated. The de novo induction of hepa-
tic genes, including albumin (Alb1) and a-fetoprotein
(Afp), in the endoderm of such cultures is dependent
on FGFs produced by the cardiac mesoderm (Jung
et al., 1999; Deutsch et al., 2001; Serls et al., 2005). We
compared the amounts of total and phosphorylated sig-
naling proteins in the explants and found that the FGFR
inhibitor SU5402 diminished the amount of P-ERK rela-
tive to total ERK (Figure 2A, lanes 1 and 2), but did not
diminish P-AKT (Figure 2A, lanes 3 and 4). Thus, signal-
ing via FGFR appears to stimulate the MAPK pathway in
the foregut endoderm-mesoderm explants, but not the
PI3K pathway. Furthermore, under conditions in which
SU5402 inhibited the MAPK pathway, but not the PI3K
pathway (Figure 2A), Alb1 induction in the explants
was strongly inhibited (Figure 2D).
To further investigate the role of MAPK signaling, we
tested U0126, an inhibitor that is highly selective for
the MAPKs MEK1 and MEK2, but not 11 other kinases
tested (Favata et al., 1998; Minokawa et al., 2001). Like
SU5402, U0126 diminished the amount of P-ERK relative
to total ERK (Figure 2B, lanes 1 and 2), but did not dimin-
ish P-AKT (Figure 2B, lanes 3 and 4). Similarly, U0126
strongly inhibited the induction of Alb1 in the explants
(Figure 2E). Careful monitoring of the cultures revealed
that U0126 (or SU5402, data not shown) did not inhibit
explant growth (Figures S1A, S1B, S1D, and S1E; quan-
tified in Figure S1J; see the Supplemental Data available
with this article online), BrdU incorporation (Figures S1C
and S1F), or cell viability (Nile blue staining; data not
shown). Furthermore, when endoderm-STM explants
(without the cardiac mesoderm) were treated with FGF
and U0126, FGF-mediated induction of Alb1 was sup-
pressed (Figure 2F). We conclude that activation of the
MAPK pathway by FGF signaling in foregut endoderm
explants is necessary for the initial induction of Alb1.
Conversely, we found that the PI3K inhibitor
LY294002 diminished the amount of P-AKT relative to
total AKT (Figure 2C, lanes 1 and 2; Figures S1L and
S1P), but that it had no effect on P-ERK (Figure 2C, lanes
3 and 4). Furthermore, when explants of the ventral fore-
gut endoderm and the STM, lacking the cardiac meso-
derm, were treated with both FGF and the PI3K inhibitor
LY294002, Alb1 expression was still induced, relative to
the actin control (Figure 2G, lanes 8–10; compare with
Figure 2F). Significantly, treatment with LY294002 in-
hibited the growth of endoderm-STM explants with the
cardiac mesoderm (Figures S1G, S1H, and S1J), and ap-
optosis was only evident in isolated mesenchymal cells
that migrated away from the endoderm, not in the endo-
derm itself (Figure S1R). Treatment with LY294002 did
not markedly inhibit BrdU incorporation (Figures S1C
and S1I). Thus, we conclude that an activated PI3 kinase
pathway, implicated here in explant growth, is not
necessary for hepatic gene induction. In addition, the
MAPK and PI3K inhibitors were pathway specific, and
in repeated assays, we found no evidence for cross-
pathway regulation.
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341Figure 1. Active MAPK and PI3K Pathways in
Prospective Hepatic Endoderm Cells
(A0–D0) (Top) Immunohistochemistry (DAB-
HRP) for phospho-ERK on E8.25–E8.5 mouse
embryos with 2–5S and 8S (somite pairs), be-
fore and after hepatic specification, respec-
tively. The embryo in (D) was cultured in
DMEM containing 10% calf serum and 40
mM SU5402 for 30 min prior to P-ERK label-
ing. Dashed lines show section planes
through the lateral endoderm (l.e.), shown in
(A0)–(D0). Orange-brown staining denotes
positive signals in the endoderm and the ad-
jacent cardiac mesoderm (c. meso.). Green
arrows indicate P-ERK staining within the
l.e.; black arrows indicate P-ERK-negative
domains; h.f., head fold.
(E–F0) Immunochemistry for phospho-AKT on
4S and 8S embryos. Green arrows indicate
the P-AKT-positive ventral foregut endo-
derm, and black arrows indicate P-AKT-neg-
ative domains. (F0) Section across the dashed
line in (F), showing that P-AKT is specifically
in the lateral endoderm.To assess whether FGF/MAPK signaling is needed
continuously to maintain hepatic gene expression, we
established endoderm-STM cultures in the presence
or absence of 5 ng/ml FGF2 for 48 hr. A subset of
FGF-treated explants was withdrawn from the factor
and cultured for an additional 5 days. We found that
such explants still expressed Alb1 robustly relative to
the actin internal control (Figure 2H, lanes 7 and 8),
and we conclude that a transient FGF/MAPK signal
leads to a stable induction of the hepatic program.MAPK Signaling Elicits Hepatic Induction
in Whole-Embryo Cultures
Because so few embryonic domains were P-ERK posi-
tive at the 2–5S stage (Figure 1), we evaluated the effect
of FGF signaling inhibitors on intact embryos. We first
isolated E8.25 mouse embryos at 1–4S, prior to hepatic
induction, and cultured them in media containing
SU5402, U0126, or DMSO vehicle for 9 hr. We did not
test LY294002 due to its extensive growth inhibitory
properties. The SU5402- and U0126-treated embryosFigure 2. The FGF/MAPK Signaling Pathway,
but Not the PI3K Pathway, Activates Albumin
Expression in Endoderm Explants
(A–C) Western blots of total cell protein from
explants of the ventral endoderm, the septum
transversum mesenchyme (STM), and the
cardiac mesoderm from E8.25 (2–5S) em-
bryos, cultured for 48 hr both with and
without inhibitors of (A) FGFR signaling
(SU5402), (B) MEK1/2 (U0126), and (C) PI3K
(LY294002). Antibodies were specific to total
or phospho-ERK1/2 or -AKT; a gel lane con-
tains protein from 2–3 explants.
(D–H) RT-PCR of RNA from individual ex-
plants. (D and E) Explants of the ventral fore-
gut endoderm, the STM, and the cardiac
mesoderm isolated from 2–5S embryos and
cultured for 48 hr both with and without (D)
SU5402 and (E) U0126. (F and G) Similar ex-
plants, but without the cardiac mesoderm,
cultured for 48 hr both with and without
5 ng/ml FGF2 and with and without (F)
U0126 or (G) LY294002. (H) Explants of the en-
doderm and the STM cultured for 48 hr both
with and without 5 ng/ml FGF2 (lanes 3–6);
parallel cultures with FGF for 2 days were
then cultured without FGF for 5 days. Different
PCR cycle steps are shown in (D) and (F); in
(D)–(H), the positive control was embryonic
liver, and lane 2 in each panel is a water input
control.
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Whole-Embryo Cultures Impairs Hepatic
Induction
(A–J) Intact embryos were cultured for (A and
B) 9 hr or (C–J) 24 hr in inhibitors or DMSO car-
rier. Development appeared normal in most
embryos, except those with SU5402, in which
yolk sac vasculogenesis was impaired. (B)
RT-PCR of dissected foregut domains from
embryos cultured for 9 hr; two cycle steps
are shown. Of seven embryos cultured with
DMSO carrier, six showed high levels of albu-
min mRNA (lanes 3–8 and not shown). Of four
SU5402-cultured embryos, two showed weak
induction of albumin (lanes 9–12) and two
showed none (not shown). U0126-cultured
embryos showed either a marked deficiency
in inducing albumin (n = 2, lanes 13–16) or
a complete failure (n = 2, lanes 17–18 and
not shown). (C–J) In situ hybridization for
Afp RNA in embryos cultured 24 hr with (C–
F) DMSO or (G–J) 50 mM U0126. Yellow, boxed
areas in (C) and (G) are shown at higher mag-
nification in (D) and (H), respectively; white,
dashed lines in (D) and (H) demarcate the re-
gions through which the sections shown in
(E) and (I), respectively, pass. (F) and (J)
show the sections in (E) and (I), respectively,
at higher magnification. The red arrow points
to the vitelline vein in U0126-cultured em-
bryos, indicating normal vascular develop-
ment. (J) Afp staining in inhibitor-treated em-
bryos was weak or absent in the gut
endoderm, while it remained strong in the
yolk sac.exhibited proper growth and somite, head fold, and overt
cardiac development (Figure 3A). Hex expression in the
foregut, which is exclusive to the endoderm in this do-
main (Martinez-Barbera et al., 2000), was unaffected by
SU5402 or U0126 (Figure 3B), confirming that the drugs
did not inhibit endoderm growth or viability. By contrast,
the induction of Alb1 expression was impaired in
SU5402-treated embryos and was impaired or com-
pletely blocked in U0126-treated embryos (Figure 3B).
We next cultured 4S embryos for 24 hr so that they
reached the equivalent of E9.0, which is after liver bud
formation. Remarkably, embryos cultured in SU5402 or
U0126 exhibited the typical 70% success rate of turning,
growth, and proper heart and tail looping (Figures 3C
and 3G) seen in cultured control embryos (Tremblay
and Zaret, 2005). Also, the formation of the aorta, vitel-
line veins, neural tube, and somites appeared normal
in the U0126-treated embryos (Figures 3C, 3E, 3G, and
3I; data not shown). The control embryos (n = 5) ex-
hibited a normal hepatic diverticulum (Figures 3E and
3F), a thickening of the hepatic endoderm (Figure 3F),
and expression of Afp in most or all of the liver bud cells
(Figures 3C–3F). By contrast, the U0126-treated em-
bryos (n = 5) exhibited a smaller hepatic diverticulum
(Figure 3I) and had much less or virtually no endodermal
Afp mRNA expression (Figure 3J). Notably, Afp expres-
sion was not inhibited in the yolk sac endoderm, under-
scoring the remarkable specificity of the drug for foregutendoderm cells. Interestingly, the prospective hepatic
endoderm in the U0126-treated embryos still thickened
(Figure 3J), which is part of the normal process of liver
bud induction (Bort et al., 2006). However, later, the he-
patic diverticulum did not progress to the emergent liver
bud phase, as seen in the control embryos (Figures 3D
and 3H). To quantify the inhibitory properties of U0126
and SU5402, we determined that control embryos re-
quired an average of 18 3 0.7 mm sections to span the
entire AFP-positive hepatic endoderm domain (n = 4),
whereas two out of three SU5402-cultured embryos at
comparable stages required eight sections to span the
gut endoderm with trace Afp expression (data not
shown) and three out of three U0126-cultured embryos
required seven such sections. In summary, SU5402
and U0126 inhibited the initial induction of liver genes
in whole embryos, similar to their effect on foregut
explants, without inhibiting the initial step of hepatic
morphogenesis.
Genetic Inhibition of MAPK Signaling in the Foregut
Endoderm: Specific Loss of Prospective
Hepatic Cells
We next developed a conditional genetic approach with
the potential to inhibit FGF/MAPK signaling specifically
in the endoderm, by using two different mouse lines
that express CRE recombinase in undifferentiated endo-
derm cells. Careful analysis of staged embryos from
Signal Pathways for Endoderm Patterning
343Figure 4. Foxa3-Cre and Hex-Cre Trans-
genes Are Expressed Mosaically in Prospec-
tive Hepatic Endoderm Cells
(A–J) (A–D, F–J) Detection of b-gal activity in
embryos of the indicated genotypes and
stages. (D and J) Transverse sections of the
liver buds of embryos in (C) and (I), respec-
tively (mg, midgut). Red arrows in (A), (B),
(G), and (H) point to the lateral and medial
foregut endoderm. (A and G) Note that both
Foxa3-Cre andHex-Cre are expressed mosa-
ically in the medial and lateral prospective he-
patic endoderm cells. (E) Map of the Hex-Cre
transgene construct.crosses to mice carrying the R26R reporter gene (Sor-
iano, 1999) showed that the first line, Foxa3-Cre (Lee
et al., 2005), expresses Cre in a mosaic fashion in lateral
and medial prospective hepatic endoderm cells at the 2–
5S stages (E8.25) as well as in the yolk sac (Figure 4A).
By E8.5 (8–10S), Foxa3-Cre was active in most of the
liver progenitors and tail bud (Figure 4B), and by E9.5
(25S), it was active in most liver bud descendants, the
midgut, and tail bud (Figures 4C and 4D). The second
mouse line, which we created, is designated Hex-Cre
(Figure 4E). Hex-Cre embryos can also initiate Cre ex-
pression mosaically in the lateral and medial endoderm
by 2–5S (Figure 4G, red arrows; section analysis not
shown), but not in the yolk sac. By 10S,Hex-Cre is active
mosaically in foregut liver progenitors (Figure 4H, red ar-
row), and by 25S, CRE marks about 40% of the hepato-
blasts in the liver bud as well as in midgut and tail bud
cells (Figures 4I and 4J).
We also employed a Spry2 conditional gain-of-func-
tion transgene,Spry2-GOF (Figure 5A). Prior to CRE-me-
diated recombination, this transgene expresses lacZ, but
after recombination it expresses a bicistronic mRNA con-
taining both mouse Spry2 and human placental alkaline
phosphatase (PLAP) coding sequences, separated by
an internal ribosomal entry site (IRES). PLAP is detected
by a histochemical stain and thus is a reporter for ectopic
Spry2 expression. Next, we generated Foxa3-Cre;Spry2-
GOFandHex-Cre;Spry2-GOFembryos toassess the cell-
intrinsic, mosaic response to ectopic Spry2 expression.
When the Cre transgenes were used to activate
Spry2-GOF, midgut and tail bud cells were robustly
marked by PLAP staining, indicative of Spry2 expres-
sion (Figures 5D, 5E, 5I, and 5H, mg and tb). The pres-
ence of PLAP-positive cells in the non-liver midgut
endoderm (Figures 5D, 5E, and 5I, dark staining; Fig-
ure 5H, green staining) indicated that Spry2 expression
was not toxic to endoderm cells. Significantly, thestrong PLAP staining in the tail bud, which normally con-
tains high levels of P-ERK (Figure 5L, red cells; also see
Corson et al., 2003), was accompanied by a dramatic
diminution in the amount of P-ERK (Figure 5M; note
the few remaining P-ERK-positive cells, arrows).
In contrast to the presence of PLAP-positive cells in
the midgut and tail bud, very few PLAP-positive cells
were detected in regions corresponding to the liver bud
at 14–15S (compare the yellow boxed area of the liver
bud in Figures 5D, 5E, and 5I to a Foxa3-Cre;R26R em-
bryo in Figure 5B). Sections through the liver bud of
Foxa3-Cre;Spry2-GOF embryos confirmed that there
were few PLAP-positive cells (Figures 5F and 5G, arrow-
heads). At later stages, the liver inFoxa3-Cre;Spry2-GOF
embryos was well developed, expressed Alb1, and was
b-gal positive (Figures 5N–5Q), reflecting the normal
development and survival of hepatic cells in which
the Spry2-GOF transgene had not recombined. As ex-
pected, the tail buds of such embryos were b-gal nega-
tive (Figure 5O). Together, these data indicate that
SPRY2-mediated diminution of P-ERK is not necessarily
inhibitory to cell survival, and that the absence of liver
bud cells expressing the activatedSpry2-GOF transgene
was due to a failure of prospective hepatic progenitors
expressing the transgene to persist in development.
A clue as to what might be happening to liver progen-
itors that ectopically expressed Spry2 came from our
observation that in 15S Hex-Cre;Spry2-GOF embryos,
a few PLAP-expressing cells were present near the gut
lumen of the liver bud (Figures 5J and 5K, red arrows).
These cells were round and appeared to be in the pro-
cess of being shed into the lumen; this was also seen
in Foxa3-Cre;Spry2-GOF embryos (Figure 5F, arrow-
head; see below for earlier stages). The shedding was
specific to the liver bud region and was not evident in
other gut domains that extensively expressed the acti-
vated Spry2-GOF transgene (Figure 5H). Since the
Developmental Cell
344Figure 5. Ectopic Expression of Spry2-GOF
in the Endoderm Causes a Loss of Hepatic
Progenitor Cells, but Not Midgut or Tail Bud
Cells
(A) Map of the Spry2-GOF transgene before
and after Cre-mediated activation.
(B) Expression of the Foxa3-Cre transgene,
detected by b-gal activity from the activated
R26R reporter allele.
(C–K) (C) Section through the liver bud of the
embryo in (B). Mosaic activation of Spry2-
GOF in the endoderm due to recombination
mediated by (D–H) Foxa3-Cre or (I–K) Hex-
Cre and detected by (D, E, and I–K) PLAP
activity or (F–H) PLAP antigen localization,
which was apical. The yellow box demarcates
the liver bud in (B), (D), (E), and (I); the midgut
(mg) and tail bud (tb) are noted. Dashed lines
in (D), (E), and (I) indicate section planes in the
panels noted. Few (arrowheads or arrows)
PLAP-positive liver bud cells are evident in
(F), (G), (J), and (K); the white arrowhead in
(F) and the red arrows in (K) denote PLAP-
positive cells being shed from the liver bud.
Extensive PLAP staining in the midgut endo-
derm is shown in (D), (E), (H), and (I) and
shows that activation of Spry2-GOF is not
cytotoxic.
(L and M) Tail bud region from wt and Foxa3-
Cre;Spry2-GOF embryos stained for (L) P-
ERK or (M) P-ERK and PLAP, showing that
activation of Spry2-GOF inhibits phosphory-
lation of ERK, but not cell loss there.
(N–Q) Transverse sections of 30S embryos of
designated genotypes; immunohistochemis-
try for b-gal shows that cells with the unre-
combined Spry2-GOF transgene are in the
liver bud, but not the tail bud, of Foxa3-
Cre;Spry2-GOF embryos. (Q) Boxed portion
of (O) showing Alb1 expression in the liver
bud.phenotype was observed with both Cre transgenes, it is
specific to endoderm cells.
An analysis of Foxa3-Cre;Spry2-GOF embryos at
E8.25 (4S), around the time when the Spry2-GOF trans-
gene is first activated, revealed a mosaic diminution of
P-ERK in the lateral foregut endoderm (Figures 6A and
6B). Further studies demonstrated that the cells ex-
pressing PLAP did not coexpress P-ERK (Figure 6D,
green arrows; and data not shown). By 8S, such cells
did coexpress P-AKT (Figures 6M–6O; see the yellow
apical region of cells in the confocal image in Figure 6O).
This demonstrates that SPRY2 specifically inhibits
P-ERK, but not P-AKT, similar to the specificity we ob-
served with FGFR and MAPK inhibitors (Figure 2). Note
that at 4S, the PLAP-positive cell in Figure 6D (upper
left, green arrow) appears to be partly shed from the ep-
ithelium. We further found that PLAP-positive lateral en-
doderm cells that express the activated Spry2-GOF
transgene at the time of hepatic induction (Figures 6E–
6G, green arrow) are positive for cleaved caspase-3
prior to being shed from the endodermal epithelium
(Figure 6H, bracketed region; note the disrupted epithe-
lium in Figure 6F). However, activation of Spry2-GOF in
the tail bud, where it efficiently suppresses P-ERK (Fig-
ures 5L and 5M), did not lead to overt expression of
cleaved caspase-3 (Figure 6I; see the few positive cells,denoted by arrows, amidst the green PLAP-positive
cells). Furthermore, shedding of endodermal cells does
not appear to involve AKT signaling, since ectopic
Spry2-GOF expression did not induce P-AKT preco-
ciously in 4S embryos (Figures 6J–6L). In summary, our
data on Foxa3-Cre;Spry2-GOF and Hex-Cre;Spry2-
GOF embryos that are mosaic for ectopic Spry2 expres-
sion indicate that during the period of hepatic induction,
the prospective hepatic progenitor cells that fail to re-
ceive an FGF/MAPK signal do not persist within a popu-
lation of properly differentiating cells.
Discussion
Elucidating the regulatory pathways that govern endo-
derm tissue induction is an important goal, as such
knowledge can help guide the differentiation of stem
cells and other progenitors for therapeutic purposes.
Our combined in vivo-genetic, whole-embryo culture,
and tissue explant approaches provide evidence that
FGF-mediated induction of hepatic genes operates
through the MAPK pathway, not the PI3K pathway.
This is despite the fact that the PI3K pathway is acti-
vated in the foregut endoderm and confers FGF respon-
siveness in certain other tissue contexts (Carballada
et al., 2001), and that the MAPK pathway is not activated
Signal Pathways for Endoderm Patterning
345Figure 6. Shedding from the Epithelium of
Prospective Hepatic Endoderm Cells in
which Spry2-GOF Is Activated
(A and B) 4S-stage wt and Foxa3-Cre;Spry2-
GOF embryos stained for P-ERK. The dashed
line in (B) indicates the section plane in the
bright field in (C).
(C) The lateral foregut endoderm is demar-
cated by the boxed region; green arrows
point to PLAP-positive cells shown at higher
magnification in (D).
(D) PLAP and P-ERK double immunofluores-
cence showing that cells expressing the acti-
vated Spry2-GOF transgene (green stain for
PLAP) are negative for P-ERK (red). The
PLAP-positive cell in the upper left (green
arrow) is being shed from the endodermal
epithelium, demarcated by a dotted line.
(E–H) A 6S Foxa3-Cre;Spry2-GOF embryo
stained for PLAP. (E) Whole mount showing
PLAP activity mainly on the left side (image
right side) of the foregut endoderm of this em-
bryo, which was unusual but allowed us to
compare PLAP-positive and -negative endo-
derm domains in the same embryo. (F) Bright-
field view of the section plane shown in (E).
Note the defect in morphology of the left lat-
eral endoderm (right side of the picture; yel-
low bracket). Immunostaining of the section
in (F) for (G) PLAP and for (H) cleaved cas-
pase-3 shows that lateral endoderm cells in
which Spry2-GOF is activated, in green, are
becoming apoptotic.
(I) Tail bud section from a 15S Foxa3-
Cre;Spry2-GOF embryo stained for PLAP
and cleaved caspase-3, showing that activation of Spry2-GOF and diminution of P-ERK (see Figure 5M) does not obligatorily lead to apoptosis.
A few positive cells (red) are denoted by arrows.
(J–O) 4S and 8S Foxa3-Cre;Spry2-GOF embryos double stained for P-AKT and PLAP. (L and O) Confocal section analyses show no endodermal
P-AKT staining at 4S, even in cells expressing PLAP ([L], green cells/arrows), whereas at 8S, P-AKT and PLAP can be coexpressed in individual
cells ([O], yellow cells/arrows). The endoderm is demarcated by a dotted line.by FGF signaling in yet other contexts (Corson et al.,
2003). We suggest that the inherent ability of FGF to ac-
tivate MAPK and not PI3K in the foregut endoderm helps
define the intracellular network that endows endoderm
cells with the competence to induce liver, and thereby
helps explain how a common signal such as FGF elicits
a specific cellular response.
We found that the prospective hepatic endoderm cells
in the lateral foregut become P-ERK positive at about
the 2S stage and remain P-ERK positive as they move
ventrally into the foregut (Figure 1). Notably, at the
same stage of development, adjacent to these lateral
domains, Fgf8 and Fgf10 show a similar dynamic pattern
of expression in the cardiac mesoderm (Crossley and
Martin, 1995; Kelly et al., 2001; Cai et al., 2003). By the
8S stage, Fgf1, Fgf2, and Fgf8 expression spans the
ventral endoderm of the anterior intestinal portal (Jung
et al., 1999), which is also P-ERK positive. Therefore,
there is a strong correlation between the expression of
different FGF ligands and P-ERK activation during the
period of hepatic specification. By contrast, P-AKT
was not evident in the foregut endoderm until the 8S
stage, by which time liver genes have been activated.
Mosaic inhibition of FGF signaling in prospective he-
patic endoderm cells via ectopic expression of Spry2 re-
sults in the rapid elimination of cells, prior to and during
the period in which hepatic genes are normally induced.
Importantly, we showed that this effect of ectopic Spry2expression is not an obligatory consequence of inhibi-
tion of P-ERK in the endoderm (Figure 5H) or an obliga-
tory apoptotic response (Figure 6I), but rather is specific
to the prospective hepatic endoderm cells. Our data fur-
ther suggest that apoptosis of prospective hepatic en-
doderm cells occurs before they are shed from the endo-
derm (Figure 6H). These observations are consistent
with studies showing that apoptotic cells are extruded
from an epithelium by the concerted contraction of
neighboring cells (Rosenblatt et al., 2001). We recently
observed a similar phenomenon in the liver bud of chi-
meric embryos generated from Hex2/2 ES cells injected
into wild-type blastocytes. Initially, theHex2/2 cells pop-
ulate the liver bud, but fail to maintain hepatic differenti-
ation, are shed from the epithelium, and die (Bort et al.,
2006). In compensation, the surrounding wild-type he-
patic endoderm cells increase their replication rate,
showing that they possess regenerative capacity at
this early stage. Likewise, in the endoderm-Cre;Spry2-
GOFembryos, in which mosaicSpry2expression causes
prospective hepatic endoderm cells to undergo apopto-
sis, the shed cells are rapidly replaced by Spry2-nonex-
pressing cells. Shedding of cells from the developing
Drosophila wing epithelium has also been observed in
mosaic cell clones that are deprived of BMP signaling
(Gibson and Perrimon, 2005; Shen and Dahmann, 2005).
Interestingly, we did not observe similar cell elimi-
nation in SU5402- and U0126-treated embryos and
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served in the hepatic endoderm of Hex2/2 embryos, in
which all of the cells are Hex null and the improperly dif-
ferentiating cells persist (Bort et al., 2006). In both the in-
hibitor-treated embryos described here and the Hex null
embryos, the entire endodermal epithelium is affected;
therefore, local aberrations in epithelial cell interactions,
the likely cause of cell shedding in mosaics, apparently
do not occur. Alternatively, it is possible that cells in
the prospective hepatic endoderm survive after treat-
ment with MAPK inhibitors because of a cell nonauton-
omous effect; e.g., aberrant induction of an endoderm
cell survival signal from the cardiac mesoderm, in which
P-ERK was also detected (Figures 1C and 6D).
Although FGFs constitute a proliferative signal for the
endoderm shortly after tissue patterning (Bhushan et al.,
2001) and MAPK signaling can stimulate cell prolifera-
tion (Lovicu and McAvoy, 2001; Lavine et al., 2005), we
found that FGF/MAPK signaling initiates hepatic differ-
entiation and that this is separable from the effects on
cell proliferation and growth. Recently, MAPK localiza-
tion in the cytoplasm was associated with differentiation
in Drosophila wing development, whereas MAPK locali-
zation in the nucleus was associated with proliferation
(Marenda et al., 2006). In accord, we found that P-ERK
is predominantly cytoplasmic in the prospective hepatic
endoderm (Figures 1A–1C; Figure 6D).
Our data indicate that the MAPK and P-AKT pathways
are induced separately in the foregut endoderm and that
they do not crossregulate at the initial stage of tissue pat-
terning. We note that the liver, lung, and ventral pancreas
are patterned in adjacent regions of the foregut endo-
derm, and that all three exhibit similar initial morphoge-
netic transitions of the endodermal epithelium (Bort
et al., 2006). Thus, if a broad morphogenetic PI3K/AKT
signal is superimposed on varying levels of FGF/MAPK
signaling that pattern the ventral foregut endoderm
(Deutsch et al., 2001; Serls et al., 2005), it could explain
our finding that the signals in the hepatic endoderm are
coordinate, but not crossregulating, during the initiation
of hepatogenesis. Our studies underscore the impor-
tance of understanding endoderm cell specification so
that different parameters of the differentiation of stem
cells and other progenitors can be controlled at will.
Experimental Procedures
Endoderm Tissue Explants and Whole-Embryo Cultures
Embryo age was estimated by designating noon of the day on which
a vaginal plug was detected as embryonic day (E) 0.5. Endoderm ex-
plant and whole-embryo cultures and Nile blue sulfate, BrdU, and
TUNEL labeling were as described (Gualdi et al., 1996; Deutsch
et al., 2001; Bort et al., 2004; Tremblay and Zaret, 2005). LY294002
and U0126 were purchased from Cell Signaling Techologies;
SU5402 was purchased from Calbiochem. Explant image sizes
were measured after 24 hr of culture by using the Image-pro PLUS
program.
Histology, Western Blot, and RT-PCR Analysis
Whole-mount immunochemistry was as described (Corson et al.,
2003); primary antibodies against phosphorylated ERK1/ERK2 and
AKT (Cell Signaling Tech., Cat #9101 and #9275) and PLAP (GeneTex
#72703) were used at a 1:350 dilution. Alexa Fluor secondary anti-
bodies (Molecular Probes) for immunofluorescence (Bort et al.,
2006) were used at a 1:500 dilution, and primary antibodies to
PLAP and cleaved caspase-3 (Cell Signaling #9661) were used at
a 1:200 dilution. For Western blots with ERK and AKT antibodies(Cell Signaling Tech.), 2–3 cultured embryonic explants were pooled
and rinsed with cold PBS, mixed with SDS sample buffer, run on
SDS-8% polyacrylamide gels, and transferred to PVDF membranes
(Immobilon-P, Millipore). HRP-conjugated secondary antibody was
used at a 1:40,000 dilution, and signals were detected by using the
Visualizer detection kit (Chemicon). Embryo staining for X-Gal and
PLAP activity was performed according to standard procedures
(Nagy et al., 2003). Whole-mount in situ hybridization (Wilkinson,
1992) was performed with an Afp1 probe (Waldrip et al., 1998).
RNA was isolated by using the RNeasy Micro Kit (Qiagen), reverse
transcribed with oligo-dT primers, and subjected to PCR as de-
scribed (Gualdi et al., 1996). PCR cycle ranges for each gene were
determined by first analyzing actinmRNA in each sample at three cy-
cle steps, over a nine cycle range, to ensure that the reactions were
exponential. Other genes were assayed likewise, and cycle ranges
were adjusted by comparison to the actin level. Primers are de-
scribed by Deutsch et al. (2001).
Hex-Cre and Spry2-GOF Transgenic Lines
The Hex-Cre transgene construct (Figure 4E) contains one copy of
the Hex B6 intronic enhancer (Rodriguez et al., 2001) inserted up-
stream of the hsp68 promoter and a second copy inserted down-
stream of an IRES-GFP, all in pKSII (Stratagene). The Cre segment
of pturboCRE (Sauer and Henderson, 1990) was inserted between
the hsp68 and IRES sequences. The construct was excised from
the vector with BglII and NotI and was used to generate transgenic
mice (Clouthier et al., 1997). Founders were identified by PCR with
CRE primers (50-tggaaaatgcttctgtccgtttgc-30 and 50-aacgaacctggtc
gaaatcagtg-30) and bred to C57BL6/J mice. Two different founder
lines that produced consistent patterns of expression, as deter-
mined by crossing to R26R mice (Soriano, 1999), were used here.
To produce mice carrying the Spry2-GOF transgene, the Z/AP
construct (Lobe et al., 1999) was modified by inserting a mouse
Spry2 cDNA upstream of an IRES, followed by the PLAP cDNA
(Figure 5A). ES cells were electroporated with the construct, and
clones with a single insertion were selected and screened for lacZ
expression before CRE-mediated recombination and PLAP activity
after such recombination. Chimeric mice were produced by the
Stanford Transgenic Facility by injection of ES clones into C57BL/
6 embryos. The offspring of one chimera were used to establish
the Spry2-GOF line used in this study. Further details will be pub-
lished elsewhere (G.M. and G.R.M., unpublished data).
When Hex-Cre was crossed onto the Spry2-GOF background,
many of the resulting embryos exhibited widespread activation of
Spry2-GOF. Similar background-dependent effects on Cre expres-
sion have been described for other Cre transgenes (Hebert and
McConnell, 2000); only embryos displaying activated Spry2-GOF
expression patterns similar to those seen in the Hex-Cre;R26R
embryos shown in Figures 4F–4I are presented here.
Supplemental Data
Supplemental Data include studies on mouse embryo foregut ex-
plants showing that inhibition of the PI3K pathway, but not the
MAPK pathway, impairs explant growth and are available at http://
www.developmentalcell.com/cgi/content/full/11/3/339/DC1/.
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